Please try another search
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Name | Age | Since | Title |
---|---|---|---|
Simon Nebel | 55 | 2017 | Independent Chairman of Supervisory Board |
Ulrich Kinzel | 59 | 2022 | Independent Member of Supervisory Board |
Eva Hofstadter-Thalmann | - | 2023 | Member of Supervisory Board |
Julian Crane | - | - | Member of Scientific Advisory Board |
Talin Barisani | - | - | Member of Scientific Advisory Board |
Elisabeth Lackner | 50 | 2022 | Independent Member of Supervisory Board |
Ron Eccles | - | - | Member of Scientific Advisory Board |
Balamurali Ambati | - | - | Member of Scientific Advisory Board |
Brigitte Ederer | 67 | 2018 | Independent Vice Chairwoman of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review